Presentation is loading. Please wait.

Presentation is loading. Please wait.

A) 50100150200250 -80 -60 -40 -20 0 20 40 60 80 Average TC by UC and RA TC difference (RA-UC) 50100150200250 -80 -60 -40 -20 0 20 40 60 80 Average TC by.

Published byJulianna Horn Modified over 8 years ago

Similar presentations

Presentation on theme: "A) 50100150200250 -80 -60 -40 -20 0 20 40 60 80 Average TC by UC and RA TC difference (RA-UC) 50100150200250 -80 -60 -40 -20 0 20 40 60 80 Average TC by."— Presentation transcript:

1 a) 50100150200250 -80 -60 -40 -20 0 20 40 60 80 Average TC by UC and RA TC difference (RA-UC) 50100150200250 -80 -60 -40 -20 0 20 40 60 80 Average TC by UC and BC TC difference (BC-UC) 50100150200250 -80 -60 -40 -20 0 20 40 60 80 Average TC by UC and FPLC TC difference (FPLC-UC) RMSE =13.9 RMSE =30.4 RMSE =16.4 50100150200250 50 100 150 200 250 RA UC (Cholesterol mg/dl) r 2 =0.95 50100150200250 50 100 150 200 250 FPLC UC (Cholesterol mg/dl) r 2 =0.97 50100150200250 50 100 150 200 250 BC UC (Cholesterol mg/dl) r 2 =0.95 Supplementary Figure 1.

2 b) 255075100125150175 -60 -40 -20 0 20 40 60 Average LDL C by UC and FPLC LDL C difference (FPLC-UC) 255075100125150175 -60 -40 -20 0 20 40 60 Average LDL C by UC and RA LDL C difference (RA-UC) 255075100125150175 -60 -40 -20 0 20 40 60 Average LDL C by UC and BC LDL C difference (BC-UC) RMSE =13.9RMSE =7.6RMSE =14.2 r 2 =0.88 0255075100125150175 0 25 50 75 100 125 150 175 FPLC UC (LDL-C mg/dl) 0255075100125150175 0 25 50 75 100 125 150 175 RA UC (LDL-C mg/dl) r 2 =0.95 0255075100125150175 0 25 50 75 100 125 150 175 BC UC (LDL-C mg/dl) r 2 =0.84

3 c) 1020304050607080 -60 -40 -20 0 20 40 60 Average HDL C by UC and FPLC HDL C difference (FPLC-UC) 1020304050607080 -60 -40 -20 0 20 40 60 Average HDL C by UC and RA HDL C difference (RA-UC) 1020304050607080 -60 -40 -20 0 20 40 60 Average HDL C by UC and BC HDL C difference (BC-UC) RMSE =12.4RMSE =16.0RMSE =24.0 r 2 =0.58 102030405060708090100 10 20 30 40 50 60 70 FPLC UC (HDL C mg/dl) r 2 =0.72 102030405060708090100 10 20 30 40 50 60 70 RA UC (HDL C mg/dl) r 2 =0.77 102030405060708090100 10 20 30 40 50 60 70 Biochemical UC (HDL C mg/dl)

4 d) 50100150200250 -80 -60 -40 -20 0 20 40 60 80 Average TG by UC and FPLC TG difference (FPLC-UC) 50100150200250 -80 -60 -40 -20 0 20 40 60 80 Average TG by UC and RA TG difference (RA-UC) 50100150200250 -80 -60 -40 -20 0 20 40 60 80 Average TG by UC and BC TG difference (BC-UC) RMSE =22.6RMSE =12.0RMSE =18.7 r 2 =0.96 050100150200250 0 50 100 150 200 250 FPLC UC (TG mg/dl) r 2 =0.96 050100150200250 0 50 100 150 200 250 RA UC (TG mg/dl) r 2 =0.89 050100150200250 0 50 100 150 200 250 BC UC (TG mg/dl)

Download ppt "A) 50100150200250 -80 -60 -40 -20 0 20 40 60 80 Average TC by UC and RA TC difference (RA-UC) 50100150200250 -80 -60 -40 -20 0 20 40 60 80 Average TC by."

Similar presentations

Electronic Supplementary Material (ESM) Electronic Supplementary Figure 1. Plasma apoCI is associated with increased survival of patients with severe sepsis.

Electronic Supplementary Material (ESM) Electronic Supplementary Figure 1. Plasma apoCI is associated with increased survival of patients with severe sepsis.
ATP III Guidelines Specific Dyslipidemias. 2 Specific Dyslipidemias: Very High LDL Cholesterol (  190 mg/dL) Causes and Diagnosis Genetic disorders –Monogenic.

ATP III Guidelines Specific Dyslipidemias. 2 Specific Dyslipidemias: Very High LDL Cholesterol (  190 mg/dL) Causes and Diagnosis Genetic disorders –Monogenic.
Background  Hypertrigliceridaemia is common in patients with HIV, especially those taking protease inhibitors (PIs) or with lipodystrophy.  Although,

Background  Hypertrigliceridaemia is common in patients with HIV, especially those taking protease inhibitors (PIs) or with lipodystrophy.  Although,
P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.
Weng TC, et al. J Clin Pharm Ther 2010;35:139-51.

Weng TC, et al. J Clin Pharm Ther 2010;35:
Figure I. FPLC FXN 29 33 34 35 36 29 33 34 35 36 + D-4F Sc D-4F STOKES DIAMETER nm 17 12.2 10.4 8.2 7.1 HDL PEAK HDL PEAK C C P 30K.

Figure I. FPLC FXN D-4F Sc D-4F STOKES DIAMETER nm HDL PEAK HDL PEAK C C P 30K.
Women and Cholesterol What You Need to Know. Age: 45 Women and Cholesterol: What You Need to Know HDL: 60 mg/dL and above LDL: Below 100 mg/dL GoodBad.

Women and Cholesterol What You Need to Know. Age: 45 Women and Cholesterol: What You Need to Know HDL: 60 mg/dL and above LDL: Below 100 mg/dL GoodBad.
Lipoproteins/Particles

Lipoproteins/Particles
Slide Source: Lipids Online Slide Library www.lipidsonline.org Collaborative Atorvastatin Diabetes Study (CARDS) Type 2 diabetes mellitus Men and women.

Slide Source: Lipids Online Slide Library Collaborative Atorvastatin Diabetes Study (CARDS) Type 2 diabetes mellitus Men and women.
© 2003, Wellsource Inc. Effect of Ketogenic Diet on Lipid Levels (shown is LDL-C) In this group of 141 children followed for 6 months, a ketogenic diet.

© 2003, Wellsource Inc. Effect of Ketogenic Diet on Lipid Levels (shown is LDL-C) In this group of 141 children followed for 6 months, a ketogenic diet.
© 2004, Wellsource Inc. Low Carbohydrate Diet and LDL Cholesterol Levels 119 men and women, 24 weeks On the low carb diet, LDL increased slightly On low.

© 2004, Wellsource Inc. Low Carbohydrate Diet and LDL Cholesterol Levels 119 men and women, 24 weeks On the low carb diet, LDL increased slightly On low.
Lab 6 TC, LDL-C, HDL-C, and TG T.A. Bahiya Osrah

Lab 6 TC, LDL-C, HDL-C, and TG T.A. Bahiya Osrah
Cholesterol Measurement All adults should have their blood cholesterol measured every 5 years May be in non-fasting state Fasting preferred

Cholesterol Measurement All adults should have their blood cholesterol measured every 5 years May be in non-fasting state Fasting preferred
Lab (6): Lipids profile KAU-Faculty of Science- Biochemistry department Clinical biochemistry lab (Bioc 416) 2012 T.A Nouf Alshareef

Lab (6): Lipids profile KAU-Faculty of Science- Biochemistry department Clinical biochemistry lab (Bioc 416) 2012 T.A Nouf Alshareef
10/3/2014. Εμφραγμα - Στηθαγχη - Πονος στο στηθος : Εμφραγμα μυοκαρδιου λεμε την βαρυτατη εκεινη κατασταση που οφειλεται στην αποφραξη που μπορει να γινει.

10/3/2014. Εμφραγμα - Στηθαγχη - Πονος στο στηθος : Εμφραγμα μυοκαρδιου λεμε την βαρυτατη εκεινη κατασταση που οφειλεται στην αποφραξη που μπορει να γινει.
Liver cholesterol (mg/g)

Liver cholesterol (mg/g)
Parameters BD PP CP TC (mg. dl-l) ± * ± 5.8

Parameters BD PP CP TC (mg. dl-l) ± * ± 5.8
Dufaux, International Journal of Sports Medicine, 1982 TRIGLYCERIDES & TRAINING Increase Decrease No Change Numbers of Studies.

Dufaux, International Journal of Sports Medicine, 1982 TRIGLYCERIDES & TRAINING Increase Decrease No Change Numbers of Studies.
Supplemental Figure S1 (A) (B) Any Statin ↓Randomisation

Supplemental Figure S1 (A) (B) Any Statin ↓Randomisation
Raw data Log-transformed data Male age log age Female age log age

Raw data Log-transformed data Male age log age Female age log age

Similar presentations

Ads by Google